Evaluation of prenylated peptides for use in cellular imaging and biochemical analysis.

about

Evaluation of prenylated peptides for use in cellular imaging and biochemical analysis.

Item

http://www.wikidata.org/entity/Q39074628

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

2014年论文

@zh

2014年论文

@zh-cn

name

Evaluation of prenylated peptides for use in cellular imaging and biochemical analysis.

@en

Evaluation of prenylated peptides for use in cellular imaging and biochemical analysis.

@nl

type

Item

label

Evaluation of prenylated peptides for use in cellular imaging and biochemical analysis.

@en

Evaluation of prenylated peptides for use in cellular imaging and biochemical analysis.

@nl

prefLabel

Evaluation of prenylated peptides for use in cellular imaging and biochemical analysis.

@en

Evaluation of prenylated peptides for use in cellular imaging and biochemical analysis.

@nl

P1476

Evaluation of prenylated peptides for use in cellular imaging and biochemical analysis.

@en

P2093

Edgar A Arriaga

http://www.w3.org/2001/XMLSchema#string

Elizabeth V Wattenberg

http://www.w3.org/2001/XMLSchema#string

Joshua D Ochocki

http://www.w3.org/2001/XMLSchema#string

Mark D Distefano

http://www.w3.org/2001/XMLSchema#string

Urule Igbavboa

http://www.w3.org/2001/XMLSchema#string

W Gibson Wood

http://www.w3.org/2001/XMLSchema#string

P2860

Farnesyltransferase inhibitor as anticancer agent

Protein prenylation: molecular mechanisms and functional consequences

Enlarging the scope of cell-penetrating prenylated peptides to include farnesylated 'CAAX' box sequences and diverse cell types.

Farnesyltransferase inhibitors as anticancer agents: current status.

Biochemistry of protein prenylation.

Protein isoprenylation and methylation at carboxyl-terminal cysteine residues.

Tailoring Ras-pathway--inhibitor combinations for cancer therapy.

Isoprenoids and Alzheimer's disease: a complex relationship.

Development of farnesyltransferase inhibitors for clinical cancer therapy: focus on hematologic malignancies.

Membrane-associated farnesylated UCH-L1 promotes alpha-synuclein neurotoxicity and is a therapeutic target for Parkinson's disease.

P304

213-223

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/978-1-62703-673-3_14

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

1088

http://www.w3.org/2001/XMLSchema#string

P577

2014-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

258065595

http://www.w3.org/2001/XMLSchema#string

P698

24146406

http://www.w3.org/2001/XMLSchema#string

P932

4318554

http://www.w3.org/2001/XMLSchema#string